Amicus Therapeutics (FOLD)
(Delayed Data from NSDQ)
$10.09 USD
-0.28 (-2.70%)
Updated Nov 14, 2024 04:00 PM ET
After-Market: $10.10 +0.01 (0.10%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth A Momentum C VGM
Price, Consensus and EPS Surprise
FOLD 10.09 -0.28(-2.70%)
Will FOLD be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for FOLD based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for FOLD
Repligen Beats on Q3 Earnings & Sales, Narrows '24 Sales View
Rocket Pharmaceuticals' Q3 Earnings Beat, Pipeline in Focus
FOLD: What are Zacks experts saying now?
Zacks Private Portfolio Services
PBYI Beats Q3 Earnings & Revenue Estimates, Revises '24 View, Stock Up
Allogene's Q3 Loss Narrower Than Expected, Sales Nil
IOVA Posts Narrower-Than-Expected Q3 Loss, Amtagvi Sales Drive Top line
Other News for FOLD
WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC Acquires Shares in Amicus Therapeutics Inc
Avoro Capital Advisors LLC Adjusts Stake in Amicus Therapeutics Inc
Perceptive Advisors LLC Acquires Significant Stake in Adagio Medical Holdings Inc
Amicus Therapeutics Stock: A Deep Dive Into Analyst Perspectives (8 Ratings)
Amicus price target raised to $17 from $16 at JPMorgan